PCSK9 Cholesterol Lowering Moves Beyond Injections: FDA Approves First Oral Inhibitor, Lipfendra

For years, patients seeking to substantially reduce low-density lipoprotein cholesterol (LDL-C) by inhibiting PCSK9 had only injectable drugs to choose from. The U.S. Food and Drug Administration (FDA) has now approved Merck’s Lipfendra (enlicitide), making this lipid-lowering mechanism available as an oral therapy for the first time and potentially changing the options discussed by high-risk patients and physicians when considering treatment intensification.

Lipfendra is a once-daily cyclic peptide drug supplied as a 20-milligram tablet. It is approved for use alongside diet and exercise in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. These patients may have elevated LDL-C from birth, and some still struggle to reach treatment targets even while taking the maximum tolerated dose of statins.

PCSK9 interacts with LDL receptors on the surface of liver cells and promotes their degradation. As the number of receptors declines, LDL-C becomes more difficult to clear from the blood. Enlicitide blocks this interaction, allowing more LDL receptors to return to the cell surface and continue working. Its mechanism is similar to that of existing injectable PCSK9 drugs, but it delivers a large cyclic peptide in an oral tablet.

The approval was based on CORALreef Lipids and CORALreef HeFH, two randomized, double-blind, placebo-controlled Phase 3 trials that enrolled a total of 3,207 adults already receiving maximally tolerated statin therapy. The latter trial specifically studied heterozygous familial hypercholesterolemia. At 24 weeks, LDL-C decreased by 56% and 59% more, respectively, in the Lipfendra groups than in the placebo groups, showing that the oral formulation can still produce a substantial lipid-lowering effect.

The safety data need to be interpreted within the context of the different trials. In CORALreef Lipids, adverse reactions occurred at similar frequencies in the two groups. In CORALreef HeFH, diarrhea and dizziness were more common than in the placebo group. These findings support the short-term benefit-risk assessment underlying the approval, but they are not sufficient to fully characterize tolerability after long-term use in a broader patient population.

The more important unanswered question is whether lowering laboratory values will translate into fewer heart attacks, strokes, or cardiovascular deaths. Merck has explicitly stated that Lipfendra’s effects on cardiovascular morbidity and mortality have not been established. A cardiovascular outcomes trial enrolling more than 14,500 people is underway. The first oral PCSK9 inhibitor has crossed the thresholds of administration method and regulatory approval, but the next step that will truly determine its clinical role is demonstrating that it can improve patients’ long-term outcomes.